Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


How does Samsung bioepis rapidly develop and manufacture high quality biosimilars?

  • In: Symposium D4: Non-Biological-Complex-Drugs on Wednesday, 24 May 2017, 11:15-11:50
  • At: Stockholm (Sweden) (2017)
  • Type: Presentation
  • By: MIN, Brain Hosumg (Incheon, Korea, Republic Of)
  • Co-author(s): Brain Hosumg Min: Drug Substance Team, Samsung Bioepis, Incheon, Korea, Republic Of
  • Abstract:

    A biosimilar is a biologic product that is highly similar but not identical to its reference product. The biosimilarity between the reference product and its biosimilar is demonstrated by the similarity in their clinical effects, such as efficacy, PK, safety, and immunogenicity. The similar clinical profiles are driven by similar analytical..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses